Pharmaceutical industry

More than 2400 Canadians took to the streets of Toronto to raise an unprecedented $1.63 million for life-saving cancer research and clinical care at The Princess Margaret

Retrieved on: 
Sunday, June 16, 2024

This inclusive family and dog-friendly walk/run event has raised more than $16 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.

Key Points: 
  • This inclusive family and dog-friendly walk/run event has raised more than $16 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.
  • "I will continue to raise awareness and crucial funds to help the life-saving cancer research being done at the Princess Margaret Cancer Centre," says Brandon.
  • "I want to express my gratitude to the staff I encountered during my own cancer journey at Princess Margaret."
  • All routes passed by Princess Margaret Cancer Centre for celebratory photos, with pit stops and live entertainment along the way.

Capstone Management Group and HealingMaps Announce Joint Venture to Deliver Specialized Insurance Products for Psychedelic-Assisted Therapy Industry

Retrieved on: 
Tuesday, June 11, 2024

Miami, Florida--(Newsfile Corp. - June 11, 2024) - Capstone Management Group, a leading insurance/reinsurance program management firm, and HealingMaps Inc. (HealingMaps), a premier resource for psychedelic-assisted therapies, are excited to announce the formation of Advanced Behavioral Strategies, Inc. (ABS), a strategic joint venture to deliver innovative insurance products tailored for the burgeoning psychedelic-assisted therapy industry.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - June 11, 2024) - Capstone Management Group, a leading insurance/reinsurance program management firm, and HealingMaps Inc. (HealingMaps), a premier resource for psychedelic-assisted therapies, are excited to announce the formation of Advanced Behavioral Strategies, Inc. (ABS), a strategic joint venture to deliver innovative insurance products tailored for the burgeoning psychedelic-assisted therapy industry.
  • The psychedelic-assisted therapy industry is experiencing rapid growth, driven by increasing recognition of its potential benefits for mental health treatment.
  • "We are thrilled to partner with HealingMaps to launch ABS and offer specialized insurance products that support the advancement of psychedelic-assisted therapy," said Nino Pedrini, CEO of Capstone Management Group.
  • For more information about the new insurance products and how they can benefit your practice, please visit Capstone Management Group or HealingMaps .

InvestmentPitch Media Video Discusses Zero Candida, an Israeli FemTech Medical Device Start-Up with Plans to Apply to List on the TSX Venture Exchange

Retrieved on: 
Wednesday, June 5, 2024

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - Zero Candida, an Israeli FemTech medical device start-up, will be applying to list on the TSX Venture Exchange, with a proposed valuation of 40 million dollars Canadian.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - Zero Candida, an Israeli FemTech medical device start-up, will be applying to list on the TSX Venture Exchange, with a proposed valuation of 40 million dollars Canadian.
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • Zero Candida has a potential to become a technological leader and using its ground-breaking technology to expand boundaries of non-chemical candida treatment."
  • Zero Candida's device will bring the field of gynecology into the 21st century with hybrid medicine and technology-based diagnostics.

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

Retrieved on: 
Monday, June 17, 2024

Paris (France) and Cambridge (Massachusetts, USA), June 12, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the successful transfer of BIO101 (20-hydroxyecdysone) production to industrial scale by Seqens.

Key Points: 
  • Paris (France) and Cambridge (Massachusetts, USA), June 12, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the successful transfer of BIO101 (20-hydroxyecdysone) production to industrial scale by Seqens.
  • This batch is now available for use in Biophytis' clinical development programme to treat respiratory deterioration in patients with Duchenne Muscular Dystrophy (DMD).
  • BIO101 (20-hydroxyecdysone) has significant potential to improve respiratory capacity and quality of life in non-ambulatory patients in the advanced stages of the disease.
  • The successful transfer of production to industrial scale by Seqens strengthens our ability to provide unique therapeutic solutions.

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...

Retrieved on: 
Monday, June 17, 2024

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...

Key Points: 
  • HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...
  • The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxcyholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).
  • The ongoing multi-regional Phase 2b study (CENTRICITY, NCT05623189), now fully enrolled, evaluates the histologic benefit of HTD1801 in this same patient population.
  • “Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract SAT-227, Poster Presented June 8)

Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science

Retrieved on: 
Monday, June 17, 2024

In February 2020, Valbiotis and Nestlé Health Science entered into a global contract including:

Key Points: 
  • In February 2020, Valbiotis and Nestlé Health Science entered into a global contract including:
    a worldwide license agreement granting Nestlé Health Science exclusive commercial rights to TOTUM•63.
  • a supply agreement with Nestlé Health Science for TOTUM•63.
  • Following changes at Nestlé Health Science and the company's shift in priorities in the health nutrition market, Valbiotis and Nestlé Health Science have come to an agreement to terminate this global contract.
  • Furthermore, the agreement excludes any reimbursement of payments made to Valbiotis by Nestlé Health Science.

EQS-News: QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

Retrieved on: 
Monday, June 17, 2024

Vienna, Austria, 04 June 2024: QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.

Key Points: 
  • Vienna, Austria, 04 June 2024: QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.
  • Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention.
  • The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments.
  • The total potential transaction value may exceed EUR 500 million in form of R&D funding and success driven discovery, development, regulatory and commercial milestones.

EQS-News: Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101

Retrieved on: 
Monday, June 17, 2024

The SAB has been established to provide advice and direction to the Company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD), an indication with high unmet medical need.

Key Points: 
  • The SAB has been established to provide advice and direction to the Company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD), an indication with high unmet medical need.
  • The SAB consists of retina experts with deep knowledge and experience from both clinical practice and academia with strong track records in the development of ophthalmic drugs.
  • The advisors will consult with the Company as it advances lead compound, GAL-101, as a potential eye drop treatment for dry AMD, one of the leading causes of blindness.
  • The Company and the SAB agreed on the design, endpoints and selection criteria of the upcoming Phase 2 DREAM study, which is expected to begin in late 2024.

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity

Retrieved on: 
Monday, June 17, 2024

The primary objective of the study is to assess improvements in muscle strength of lower limbs as measured by knee extension.

Key Points: 
  • The primary objective of the study is to assess improvements in muscle strength of lower limbs as measured by knee extension.
  • Multiple secondary endpoints will also be explored such as mobility (as measured by the 6-minute walk test) and body composition (fat mass, lean body mass).
  • Biophytis is also actively engaging in the process to broaden its research capacity by including European clinical centers.
  • He is a worldwide recognized medical expert in the field of obesity and is currently President-Elect of the US-based Obesity Society.

Advanced R&D capabilities and proven efficacy of our unique fast pain-relief mouth ulcer cream

Retrieved on: 
Monday, June 17, 2024

Our mouth ulcer cream is a testament to this commitment, formulated with a proprietary blend of clinically proven ingredients that deliver comprehensive relief and promote rapid healing.

Key Points: 
  • Our mouth ulcer cream is a testament to this commitment, formulated with a proprietary blend of clinically proven ingredients that deliver comprehensive relief and promote rapid healing.
  • A recent clinical study1, conducted by our esteemed team of researchers, underscores the efficacy of our mouth ulcer cream.
  • The clinical study concluded that our mouth ulcer cream offers a superior solution for those seeking rapid relief and effective healing.
  • "This study highlights the exceptional efficacy of our mouth ulcer cream and showcases our capability as a leading R&D company.